How Computer-Aided Drug Discovery Is Leading to Revolutionary Cancer Treatment
Watch this video to learn how a collaboration between the Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics, and the Frederick National Laboratory for Cancer Research is helping to revolutionize cancer treatment and computer-aided drug discovery.
“For the DOE complex, this is the first true example that high performance computing can accelerate drug discovery, which is reinforced by making it to human trials,” said LLNL Biochemical and Biophysical Systems Group Leader Felice Lightstone , principal investigator for the project.
Transcript
00:00:00 finding new treatments for diseases like cancer is a complex timeconsuming challenge it can take years of research that costs billions of dollars and most promising drugs fail before even getting to Market but hope arises in a groundbreaking collaboration between Lawrence Livermore National Laboratory biotech company Bridge bio oncology Therapeutics and the Frederick National
00:00:24 Laboratory for cancer research for the first time a department of energy National Lab along Ong with its research and Industry Partners has combined worldclass supercomputing scientific knowhow and a revolutionary drug Discovery platform developed at Livermore that pairs artificial intelligence with traditional physics-based tools to reach a new
00:00:45 frontier in cancer research the result of this collaboration is a novel drug candidate designed to Target a protein called kras whose genetic mutations are linked to about 30% of all cancers the drug is designed to Target Kass at its core inhibiting it from promoting outof control tumor growth the next step in the collaboration for the first time in the known history of the doe a drug
00:01:11 co-designed at a National Laboratory is headed from the lab to human clinical trials so we think this is a very important milestone for Lawrence lore National Lab and the department of energy because it really showcases in collaboration with Bridge bio we're able to co-design a drug candidate that went from D FDA application to First dose in human and it showcases how high
00:01:37 performance Computing can really accelerate drug Discovery and development and have an impact in US industry at llnl researchers have harnessed the power of supercomputing for drug design by creating the Livermore computer AED drug Discovery platform elcad simulates molecular interactions and finds the most promising compounds to fight dis disease
00:02:01 using high performance Computing and AI this process that used to take years can now be done in weeks the advantage of the machine is that it can go through multiple iterations of what those possibilities are much faster than us making every single molecule and testing the molecule in a system which is timec consuming and expensive so just if that AI allows you to get rid of
00:02:25 possibilities that are never going to happen right that is a big plus because then you're concentrating your your power only on the things that have potential while this partnership centers around finding potential cures it's also about rewriting The Narrative of cancer treatment development in the coming years this collaboration will continue to seek new compounds for other protein
00:02:47 targets and develop new drug candidates with the combined expertise of llnl scientists research institutions and companies like Bridge biooncology Therapeutics supercomputing and AI AED drug discover Discovery could unlock new medical insights and point to exciting future developments we could accelerate the discovery of Cancer Treatments quickly and routinely find counter
00:03:09 measures for infectious disease or future pandemics and most importantly provide patients with renewed optimism together we're showing that when scientific Ingenuity and cuttingedge Technology meets with novel public private Partnerships the possibilities are endless but